Human T lymphotropic virus type 1 SU residue 195 plays a role in determining the preferential CD4+ T cell immortalization/transformation tropism

Journal of Virology

Volumn 87, Issue 16, 2013, Pages 9344-9352

  Kannian, Priya ^a   Fernandez, Soledad ^b   Jones, Kathryn S ^c   Green, Patrick L ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; PROTEIN SU; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; CD4+ T LYMPHOCYTE; CELL IMMORTALIZATION; CONTROLLED STUDY; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; IN VITRO STUDY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROVIRUS; RESIDUE ANALYSIS; SURFACE PROPERTY; VIRAL TROPISM; VIRUS CELL TRANSFORMATION; VIRUS ENVELOPE;

AMINO ACID SUBSTITUTION; CD4-POSITIVE T-LYMPHOCYTES; CELL TRANSFORMATION, VIRAL; CELLS, CULTURED; DNA MUTATIONAL ANALYSIS; GENE PRODUCTS, ENV; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; MUTANT PROTEINS; RECOMBINANT FUSION PROTEINS; RETROVIRIDAE PROTEINS, ONCOGENIC; VIRAL TROPISM; VIRULENCE FACTORS;

EID: 84881246554     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01079-13     Document Type: Article

References (39)

1. Lairmore M, Franchini G. 2007. Human T-cell leukemia virus types 1 and 2, p 2071-2106. In Fields B, Knipe D, Howley P, Chanock R, Monath T, Melnick J, Roizman B, Straus S (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
2. Halin M, Douceron E, Clerc I, Journo C, Ko NL, Landry S, Murphy EL, Gessain A, Lemasson I, Mesnard JM, Barbeau B, Mahieux R. 2009. Human T-cell leukemia virus type 2 produces a spliced antisense transcript encoding a protein that lacks a classic bZIP domain but still inhibits Tax2-mediated transcription. Blood 114:2427-2438.
3. Kannian P, Green PL. 2010. Human T Lymphotropic Virus Type 1 (HTLV-1): Molecular Biology and Oncogenesis. Viruses 2:2037-2077.
4. Matsuoka M, Green PL. 2009. The HBZ gene, a key player in HTLV-1 pathogenesis. Retrovirology. 6:71.
5. Yin H, Kannian P, Dissinger N, Haines R, Niewiesk S, Green PL. 2012. HTLV-2 APH-2 is dispensable for in vitro immortalization, but functions to repress early viral replication in vivo. J. Virol.
6. Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, de Thé G. 1985. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet ii:407-410.
7. Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita K-I, Shirakawa S, Miyoshi I. 1981. Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc. Natl. Acad. Sci. U. S. A. 78:6476-6480.
8. Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, Matsumoto M, Tara M. 1986. HTLV-I associated myelopathy, a new clinical entity. Lancet i:1031-1032.
9. Yoshida M, Miyoshi I, Hinuma Y. 1982. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc. Natl. Acad. Sci. U. S. A. 79:2031-2035.
10. Araujo A, Hall WW. 2004. Human T-lymphotropic virus type II and neurological disease. Ann. Neurol. 56:10-19.
11. Bartman MT, Kaidarova Z, Hirschkorn D, Sacher RA, Fridey J, Garratty G, Gibble J, Smith JW, Newman B, Yeo AE, Murphy EL. 2008. Long-term increases in lymphocytes and platelets in human Tlymphotropic virus type II infection. Blood 112:3995-4002.
12. Orland JR, Engstrom J, Fridey J, Sacher RA, Smith JW, Nass C, Garratty G, Newman B, Smith D, Wang B, Loughlin K, Murphy EL. 2003. Prevalence and clinical features of HTLV neurologic disease in the HTLV Outcomes Study. Neurology 61:1588-1594.
13. Wang T-G, Ye J, Lairmore M, Green PL. 2000. In vitro cellular tropism of human T-cell leukemia virus type 2. AIDS Res. Hum. Retroviruses 16:1661-1668.
14. Xie L, Green PL. 2005. Envelope is a major viral determinant of the distinct in vitro cellular transformation tropism of human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2. J. Virol. 79:14536-14545.
15. Ye J, Xie L, Green PL. 2003. Tax and overlapping Rex sequences do not confer the distinct transformation tropisms of HTLV-1 and HTLV-2. J. Virol. 77:7728-7735.
16. Ghez D, Lepelletier Y, Jones KS, Pique C, Hermine O. 2010. Current concepts regarding the HTLV-1 receptor complex. Retrovirology. 7:99.
17. Ghez D, Lepelletier Y, Lambert S, Fourneau JM, Blot V, Janvier S, Arnulf B, van Endert PM, Heveker N, Pique C, Hermine O. 2006. Neuropilin-1 is involved in human T-cell lymphotropic virus type 1 entry. J. Virol. 80:6844-6854.
18. Jones KS, Fugo K, Petrow-Sadowski C, Huang Y, Bertolette DC, Lisinski I, Cushman SW, Jacobson S, Ruscetti FW. 2006. Human T-cell leukemia virus type 1 (HTLV-1) and HTLV-2 use different receptor complexes to enter T cells. J. Virol. 80:8291-8302.
19. Manel N, Kim FJ, Kinet S, Taylor N, Sitbon M, Battini JL. 2003. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell 115: 449-459.
20. Hattori S, Kiyokawa T, Imagawa K-I, Shimizu F, Hashimura E, Seiki M, Yoshida M. 1984. Identification of gag and env gene products of human T-cell leukemia virus (HTLV). Virology 136:338-347.
21. Lee TH, Coligan JE, McLane MF, Sodroski JG, Popovic M, Wong-Staal F, Gallo RC, Haseltine W, Essex M. 1984. Serological cross-reactivity between envelope gene products of type I and type II human T-cell leukemia virus. Proc. Natl. Acad. Sci. U. S. A. 81:7579-7583.
22. Delamarre L, Pique C, Pham D, Tursz T, Dokhelar MC. 1994. Identification of functional regions in the human T-cell leukemia virus type I SU glycoprotein. J. Virol. 68:3544-3549.
23. Tsukahara T, Wielgosz MM, Ratner L. 2001. Characterization of envelope glycoprotein mutants for human T-cell leukemia virus type 1 infectivity and immortalization. J. Virol. 75:9553-9559.
24. Silverman LR, Phipps AJ, Montgomery A, Fernandez S, Tsukahara T, Ratner L, Lairmore MD. 2005. In vivo analysis of replication and immunogenicity of proviral clones of human T-lymphotropic virus type 1 with selective envelope surface-unit mutations. Blood 106:3602-3608.
25. Kimata JT, Wong FH, Wang JJ, Ratner L. 1994. Construction and characterization of infectious human T-cell leukemia virus type I molecular clones. Virology 204:656-664.
26. Chen IY, McLaughlin J, Gasson JC, Clark SC, Golde DW. 1983. Molecular characterization of genome of a novel human T-cell leukaemia virus. Nature 305:502-505.
27. Jones KS, Petrow-Sadowski C, Bertolette DC, Huang Y, Ruscetti FW. 2005. Heparan sulfate proteoglycans mediate attachment and entry of human T-cell leukemia virus type 1 virions into CD4+ T cells. J. Virol. 79:12692-12702.
28. Robek MD, Ratner L. 1999. Immortalization of CD4+ and CD8+ Tlymphocytes by human T-cell leukemia virus type 1 Tax mutants expressed in a functional molecular clone. J. Virol. 73:4856-4865.
29. Sibon D, Gabet AS, Zandecki M, Pinatel C, Thete J, Delfau-Larue MH, Rabaaoui S, Gessain A, Gout O, Jacobson S, Mortreux F, Wattel E. 2006. HTLV-1 propels untransformed CD4 lymphocytes into the cell cycle while protecting CD8 cells from death. J. Clin. Invest. 116:974-983.
30. Maeda N, Palmarini M, Murgia C, Fan H. 2001. Direct transformation of rodent fibroblasts by jaagsiekte sheep retrovirus DNA. Proc. Natl. Acad. Sci. U. S. A. 98:4449-4454.
31. Silver JE, Fredrickson TN. 1983. Susceptibility to Friend helper virus leukemias in CXB recombinant inbred mice. J. Exp. Med. 158:1693-1702.
32. Pinon JD, Klasse PJ, Jassal SR, Welson S, Weber J, Brighty DW, Sattentau QJ. 2003. Human T-cell leukemia virus type 1 envelope glycoprotein gp46 interacts with cell surface heparan sulfate proteoglycans. J. Virol. 77:9922-9930.
33. Kannian P, Yin H, Doueiri R, Lairmore MD, Fernandez S, Green PL. 2012. Distinct transformation tropism exhibited by human T lymphotropic virus type 1 (HTLV-1) and HTLV-2 is the result of postinfection T cell clonal expansion. J. Virol. 86:3757-3766.
34. Chandhasin C, Coan PN, Levy LS. 2005. Subtle mutational changes in the SU protein of a natural feline leukemia virus subgroup A isolate alter disease spectrum. J. Virol. 79:1351-1360.
35. Baba E, Nakamura M, Tanaka Y, Kuroki M, Itoyama Y, Nakano S, Niho Y. 1993. Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine. J. Immunol. 151:1013- 1024.
36. Kuroki M, Nakamura M, Itoyama Y, Tanaka Y, Shiraki H, Baba E, Esaki T, Tatsumoto T, Nagafuchi S, Nakano S, et al. 1992. Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1. J. Immunol. 149:940-948.
37. Palker TJ, Riggs ER, Spragion DE, Muir AJ, Scearce RM, Randall RR, McAdams MW, McKnight A, Clapham PR, Weiss RA, et al. 1992. Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins. J. Virol. 66:5879-5889.
38. Tanaka Y, Tanaka R, Hoshino H. 1994. Identification of a novel neutralization epitope on envelope gp46 antigen of human T-cell-leukemia virustype-II (HTLV-II). Int. J. Cancer 59:655-660.
39. Haynes RA, 2nd, Phipps AJ, Yamamoto B, Green P, Lairmore MD. 2009. Development of a cytotoxic T-cell assay in rabbits to evaluate early immune response to human T-lymphotropic virus type 1 infection. Viral Immunol. 22:397-405.